This phase IV clinical trial tests how well polyethylene glycol (PEG) (also known as MiraLAX) works in improving recovery of bowel function in patients undergoing robotic-assisted urologic surgery. PEG is a type of osmotic laxative that works by drawing water into the stool in order to make it softer and easier to pass. Patients undergoing robotic-assisted urologic surgery may have lingering gastrointestinal complaints including nausea, bloating, constipation, and abdominal swelling. Giving PEG prior to surgery may return bowel function sooner and therefore alleviate or prevent some of those symptoms.
Additional locations may be listed on ClinicalTrials.gov for NCT05805436.
Locations matching your search criteria
United States
Iowa
Iowa City
University of Iowa/Holden Comprehensive Cancer CenterStatus: Active
Contact: Chad Robert Tracy
Phone: 319-335-8056
PRIMARY OBJECTIVES:
I. Determine whether the use of a preoperative laxative in addition to postoperative stool softeners and laxatives decreases time to first bowel movement after robotic urologic surgery.
II. Evaluate whether the use of a preoperative laxative in addition to postoperative stool softeners and laxatives decreases gastrointestinal-related complaints in the first week following urologic surgery.
OUTLINE: Patients are randomized in to 1 of 2 arms.
ARM I: Patients receive macrogol 3350-based iso-osmotic laxative (PEG) orally (PO) for 3 days prior to surgery and then undergo surgery, then receive PEG PO daily until first bowel movement while on study.
ARM II: Patients undergo surgery then receive PEG PO daily until first bowel movement while on study.
Trial PhasePhase IV
Trial Typesupportive care
Lead OrganizationUniversity of Iowa/Holden Comprehensive Cancer Center
Principal InvestigatorChad Robert Tracy
